FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to pulmonology. The method includes drug therapy with preparations containing magnesium, vitamins of group B and L-carnitine, while inhalation of water vapor with atomic hydrogen is carried out for 90 minutes for 10 days, the concentration of the latter is from 0.1 vol.% to 0.3 vol.%.
EFFECT: method makes it possible to increase the efficiency of rehabilitation of persons who have undergone COVID-19 by achieving positive dynamics in the form of a decrease in the manifestations of latent hypoxemia, an increase in exercise tolerance and a decrease in endothelial dysfunction.
1 cl
| Title | Year | Author | Number |
|---|---|---|---|
| A METHOD FOR THE TREATMENT OF RESPIRATORY FAILURE (HYPOXEMIA) IN PATIENTS WHO HAVE HAD AN INFECTION WITH THE SARS-CoV-2 VIRUS | 2022 |
|
RU2784998C1 |
| METHOD FOR EARLY DETECTION OF NEUROLOGICAL DISORDERS IN PATIENTS WITH COVID-19 | 2021 |
|
RU2779562C1 |
| METHOD OF TREATING HYPERCAPNIC RESPIRATORY FAILURE WITH SIGNS OF SECONDARY PULMONARY ARTERIAL HYPERTENSION | 2023 |
|
RU2806575C1 |
| 2-(IMIDAZOL-4-YL)-ETHANAMIDE OF PENTANEDIOIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING COVID-19 AND SYMPTOMS THEREOF | 2021 |
|
RU2824607C2 |
| METHOD FOR PROTECTION AGAINST CORONAVIRUS INFECTION | 2020 |
|
RU2747467C1 |
| TECHNOLOGY OF REHABILITATION-PREVENTIVE NUTRITIONAL SUPPORT IN CORONAVIRUS INFECTION | 2020 |
|
RU2735723C1 |
| METHOD FOR CORRECTING MICROCIRCULATORY DISORDERS IN POST-COVID SYNDROME | 2022 |
|
RU2791660C1 |
| METHOD OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2023 |
|
RU2808497C1 |
| Respiratory therapy method for new coronavirus infection COVID-19 in patients on artificial lung ventilation | 2020 |
|
RU2744550C1 |
| METHOD FOR ENZYME IMMUNOASSAY DETERMINATION OF THE LEVEL OF ANTIGEN-RECOGNIZING B-LYMPHOCYTE RECEPTORS REPRESENTED BY MEMBRANE-SPECIFIC RBD PROTEIN SARS-COV-2, IgG ANTIBODIES | 2021 |
|
RU2760438C1 |
